{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T21:07:35Z","timestamp":1762031255644,"version":"build-2065373602"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"GSK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s12325-025-03347-9","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T06:11:47Z","timestamp":1756447907000},"page":"5499-5514","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient and Physician Preferences for Maintenance Treatment in Advanced Non-Small Cell Lung Cancer: Insights into Treatment Selection"],"prefix":"10.1007","volume":"42","author":[{"given":"Manasee V.","family":"Shah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caitlyn T.","family":"Solem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly F.","family":"Bell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongbo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingchen","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3906-3004","authenticated-orcid":false,"given":"Umit","family":"Tapan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"issue":"3","key":"3347_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"3347_CR2","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"3347_CR3","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1158\/1055-9965.EPI-19-0221","volume":"28","author":"MB Schabath","year":"2019","unstructured":"Schabath MB, Cote ML. Cancer progress and priorities: lung cancer. Cancer Epidemiol Biomarkers Prev. 2019;28(10):1563\u201379.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"12","key":"3347_CR4","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1001\/jamaoncol.2021.4932","volume":"7","author":"AK Ganti","year":"2021","unstructured":"Ganti AK, Klein AB, Cotarla I, Seal B, Chou E. Update of incidence, prevalence, survival, and initial treatment in patients with non-small cell lung cancer in the US. JAMA Oncol. 2021;7(12):1824\u201332.","journal-title":"JAMA Oncol"},{"key":"3347_CR5","unstructured":"American Cancer Society. Lung cancer survival rates. Available from: https:\/\/www.cancer.org\/cancer\/types\/lung-cancer\/detection-diagnosis-staging\/survival-rates.html. Accessed on: May 30, 2025."},{"key":"3347_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.625688","volume":"11","author":"LF Liu","year":"2021","unstructured":"Liu LF, Li QS, Hu YX, Yang WG, Chen XX, Ma Z, et al. Prognostic model to predict overall survival for metastatic non-small cell lung cancer patients treated with chemotherapy combined with concurrent radiation therapy to the primary tumor: analysis from two prospective studies. Front Oncol. 2021;11: 625688.","journal-title":"Front Oncol"},{"issue":"1","key":"3347_CR7","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s12957-021-02340-0","volume":"19","author":"X Xu","year":"2021","unstructured":"Xu X, Li R, Zhu P, Zhang P, Chen J, Lin Y, et al. Clinical efficacy and safety of maintenance therapy for advanced non-small cell lung cancer: a retrospective real-world study. World J Surg Oncol. 2021;19(1):231.","journal-title":"World J Surg Oncol"},{"key":"3347_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15102855","author":"D de Jong","year":"2023","unstructured":"de Jong D, Das JP, Ma H, Pailey Valiplackal J, Prendergast C, Roa T, et al. Novel targets, novel treatments: the changing landscape of non-small cell lung cancer. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15102855.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"3347_CR9","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/mco2.105","volume":"2","author":"Y Cheng","year":"2021","unstructured":"Cheng Y, Zhang T, Xu Q. Therapeutic advances in non-small cell lung cancer: focus on clinical development of targeted therapy and immunotherapy. MedComm. 2021;2(4):692\u2013729.","journal-title":"MedComm"},{"key":"3347_CR10","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_389516","volume":"43","author":"S Shickh","year":"2023","unstructured":"Shickh S, Leventakos K, Lewis MA, Bombard Y, Montori VM. Shared decision making in the care of patients with cancer. Am Soc Clin Oncol Educ Book. 2023;43: e389516.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"31","key":"3347_CR11","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1200\/JCO.2017.75.2311","volume":"35","author":"T Gilligan","year":"2017","unstructured":"Gilligan T, Coyle N, Frankel RM, Berry DL, Bohlke K, Epstein RM, et al. Patient-clinician communication: American Society of Clinical Oncology consensus guideline. J Clin Oncol. 2017;35(31):3618\u201332.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3347_CR12","first-page":"1613","volume":"27","author":"JR Covvey","year":"2019","unstructured":"Covvey JR, Kamal KM, Gorse EE, Mehta Z, Dhumal T, Heidari E, et al. Barriers and facilitators to shared decision-making in oncology: a systematic review of the literature. Support Care Cancer. 2019;27(5):1613\u201337.","journal-title":"Support Care Cancer"},{"issue":"6","key":"3347_CR13","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1111\/hex.12564","volume":"20","author":"NP Tamirisa","year":"2017","unstructured":"Tamirisa NP, Goodwin JS, Kandalam A, Linder SK, Weller S, Turrubiate S, et al. Patient and physician views of shared decision making in cancer. Health Expect. 2017;20(6):1248\u201353.","journal-title":"Health Expect"},{"issue":"3","key":"3347_CR14","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1200\/JOP.2014.001434","volume":"10","author":"SJ Katz","year":"2014","unstructured":"Katz SJ, Belkora J, Elwyn G. Shared decision making for treatment of cancer: challenges and opportunities. J Oncol Pract. 2014;10(3):206\u20138.","journal-title":"J Oncol Pract"},{"issue":"1","key":"3347_CR15","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1186\/s12885-023-11598-4","volume":"23","author":"M Zhang","year":"2023","unstructured":"Zhang M, He X, Wu J, Xie F. Differences between physician and patient preferences for cancer treatments: a systematic review. BMC Cancer. 2023;23(1):1126.","journal-title":"BMC Cancer"},{"key":"3347_CR16","unstructured":"EuroQol Research Foundation. EQ-5D-3L User Guide, 2018. Available from: https:\/\/euroqol.org\/publications\/user-guides. Accessed on: May 29, 2025."},{"issue":"5","key":"3347_CR17","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1080\/01441640902827623","volume":"29","author":"JM Rose","year":"2009","unstructured":"Rose JM, Bliemer MCJ. Constructing efficient stated choice experimental designs. Transp Rev. 2009;29(5):587\u2013617.","journal-title":"Transp Rev"},{"issue":"10","key":"3347_CR18","doi-asserted-by":"publisher","DOI":"10.2196\/32365","volume":"23","author":"D Szinay","year":"2021","unstructured":"Szinay D, Cameron R, Naughton F, Whitty JA, Brown J, Jones A. Understanding uptake of digital health products: methodology tutorial for a discrete choice experiment using the Bayesian efficient design. J Med Internet Res. 2021;23(10): e32365.","journal-title":"J Med Internet Res"},{"issue":"2","key":"3347_CR19","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40273-018-0734-2","volume":"37","author":"V Soekhai","year":"2019","unstructured":"Soekhai V, de Bekker-Grob EW, Ellis AR, Vass CM. Discrete choice experiments in health economics: past, present and future. Pharmacoeconomics. 2019;37(2):201\u201326.","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"3347_CR20","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","volume":"35","author":"P Dolan","year":"1997","unstructured":"Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095\u2013108.","journal-title":"Med Care"},{"issue":"3","key":"3347_CR21","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/00005650-200503000-00003","volume":"43","author":"JW Shaw","year":"2005","unstructured":"Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care. 2005;43(3):203\u201320.","journal-title":"Med Care"},{"issue":"2","key":"3347_CR22","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s40271-018-0327-3","volume":"12","author":"S McMullen","year":"2019","unstructured":"McMullen S, Hess LM, Kim ES, Levy B, Mohamed M, Waterhouse D, et al. Treatment decisions for advanced non-squamous non-small cell lung cancer: Patient and physician perspectives on maintenance therapy. Patient. 2019;12(2):223\u201333.","journal-title":"Patient"},{"issue":"6","key":"3347_CR23","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s40271-021-00520-4","volume":"14","author":"H Collacott","year":"2021","unstructured":"Collacott H, Soekhai V, Thomas C, Brooks A, Brookes E, Lo R, et al. A systematic review of discrete choice experiments in oncology treatments. Patient. 2021;14(6):775\u201390.","journal-title":"Patient"},{"issue":"2","key":"3347_CR24","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10198-018-0955-5","volume":"20","author":"MF Janssen","year":"2019","unstructured":"Janssen MF, Szende A, Cabases J, Ramos-Go\u00f1i JM, Vilagut G, K\u00f6nig HH. Population norms for the EQ-5D-3L: a cross-country analysis of population surveys for 20 countries. Eur J Health Econ. 2019;20(2):205\u201316.","journal-title":"Eur J Health Econ"},{"key":"3347_CR25","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1477-7525-5-70","volume":"5","author":"AS Pickard","year":"2007","unstructured":"Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes. 2007;5:70.","journal-title":"Health Qual Life Outcomes"},{"issue":"12","key":"3347_CR26","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1001\/jamaoncol.2019.3338","volume":"5","author":"MJ Raphael","year":"2019","unstructured":"Raphael MJ, Robinson A, Booth CM, O\u2019Donnell J, Palmer M, Eisenhauer E, et al. The value of progression-free survival as a treatment end point among patients with advanced cancer: a systematic review and qualitative assessment of the literature. JAMA Oncol. 2019;5(12):1779\u201389.","journal-title":"JAMA Oncol"},{"issue":"8","key":"3347_CR27","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/cncr.32730","volume":"126","author":"MS von Itzstein","year":"2020","unstructured":"von Itzstein MS, Railey E, Smith ML, White CB, Sledge GW Jr, Howell JR, et al. Patient familiarity with, understanding of, and preferences for clinical trial endpoints and terminology. Cancer. 2020;126(8):1605\u201313.","journal-title":"Cancer"},{"issue":"12","key":"3347_CR28","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1093\/jnci\/djad138","volume":"115","author":"MD Brundage","year":"2023","unstructured":"Brundage MD, Booth CM, Eisenhauer EA, Galica J, Kankesan J, Karim S, et al. Patients\u2019 attitudes and preferences toward delayed disease progression in the absence of improved survival. J Natl Cancer Inst. 2023;115(12):1526\u201334.","journal-title":"J Natl Cancer Inst"},{"key":"3347_CR29","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2147\/PPA.S338840","volume":"16","author":"C Yong","year":"2022","unstructured":"Yong C, Cambron-Mellott MJ, Seal B, Will O, Maculaitis MC, Clapp K, et al. Patient and caregiver preferences for first-line treatments of metastatic non-small cell lung cancer: a discrete choice experiment. Patient Prefer Adherence. 2022;16:123\u201335.","journal-title":"Patient Prefer Adherence"},{"key":"3347_CR30","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.2147\/PPA.S248295","volume":"14","author":"B Hauber","year":"2020","unstructured":"Hauber B, Penrod JR, Gebben D, Musallam L. The value of hope: Patients\u2019 and physicians\u2019 preferences for survival in advanced non-small cell lung cancer. Patient Prefer Adherence. 2020;14:2093\u2013104.","journal-title":"Patient Prefer Adherence"},{"key":"3347_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2015.00113","volume":"5","author":"A Thomas","year":"2015","unstructured":"Thomas A, Chen Y, Yu T, Jakopovic M, Giaccone G. Trends and characteristics of young non-small cell lung cancer patients in the United States. Front Oncol. 2015;5: 113.","journal-title":"Front Oncol"},{"issue":"4","key":"3347_CR32","first-page":"199","volume":"2","author":"MJ McKeage","year":"2010","unstructured":"McKeage MJ, Jameson MB. Comparative outcomes of squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II studies of ASA404 (DMXAA) - retrospective analysis of pooled data. J Thorac Dis. 2010;2(4):199\u2013204.","journal-title":"J Thorac Dis"},{"issue":"11","key":"3347_CR33","doi-asserted-by":"publisher","first-page":"e1075","DOI":"10.1093\/oncolo\/oyad170","volume":"28","author":"EN Smyth","year":"2023","unstructured":"Smyth EN, John J, Tiu RV, Willard MD, Beyrer JK, Bowman L, et al. Clinicogenomic factors and treatment patterns among patients with advanced non-small cell lung cancer with or without brain metastases in the United States. Oncologist. 2023;28(11):e1075\u201391.","journal-title":"Oncologist"},{"issue":"1","key":"3347_CR34","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1186\/s12885-024-12126-8","volume":"24","author":"HA Divan","year":"2024","unstructured":"Divan HA, Bittoni MA, Krishna A, Carbone DP. Real-world patient characteristics and treatment patterns in US patients with advanced non-small cell lung cancer. BMC Cancer. 2024;24(1):424.","journal-title":"BMC Cancer"},{"issue":"5","key":"3347_CR35","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.9655","volume":"5","author":"X Ma","year":"2022","unstructured":"Ma X, Bellomo L, Hooley I, Williams T, Samant M, Tan K, et al. Concordance of clinician-documented and imaging response in patients with stage IV non-small cell lung cancer treated with first-line therapy. JAMA Netw Open. 2022;5(5): e229655.","journal-title":"JAMA Netw Open"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03347-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03347-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03347-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T21:02:44Z","timestamp":1762030964000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03347-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["3347"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03347-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"assertion":[{"value":"15 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Manasee V. Shah, Caitlyn Solem, Anne Liao, and Kelly F. Bell are employees of and may hold stock in GSK. Yao Wang, Hongbo Yang, and Yan Meng are employees of Analysis Group, and Mingchen Ye was an employee of Analysis Group at the time of the study, which received consulting fees from GSK to conduct this study. Umit Tapan has received an educational grant from Pfizer, served as an advisory board member for Sanofi\/Genzyme\/Regeneron and Pfizer, served as a speaker at AstraZeneca- and TD Cowen-sponsored symposia, and is an outside consultant for GSK.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study received institutional board approval from Pearl IRB on November 23, 2022 and was conducted in accordance with the protocol, applicable regulations, and guidelines governing clinical study conduct and the ethical principles of the Declaration of Helsinki. All subjects provided informed consent to participate in the study. No identifying information was collected.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}